Summary 
of 
risk 
management 
plan 
for 
Sitagliptin/Metformin  Accord  50/850 mg,  50/1000 mg 
film-coated tablets 
This  is  a  summary  of  the  risk  management  plan  (RMP)  for  Sitagliptin/Metformin  Accord 
50/850 mg,  50/1000 mg 
film-coated 
tablets.  The  RMP  details 
important 
risks  of 
Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets, how these risks can be 
minimised,  and  how  more  information  will  be  obtained  about  Sitagliptin/Metformin  Accord 
50/850 mg, 50/1000 mg film-coated tablets risks and uncertainties (missing information). 
Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets’ prescribing information 
(SmPC/  PIL)  give  essential  information  to  healthcare  professionals  and  patients  on  how 
Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets should be used. 
This summary of the RMP for Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated 
tablets should be read in the context of all this information including the assessment report of the 
evaluation and its plain-language summary, all which is part of the European Public Assessment 
Report (EPAR).  
Important  new  concerns  or  changes  to  the  current  ones  will  be  included  in  updates  of 
Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets’ RMP. 
I. The medicine and what it is used for 
Sitagliptin/Metformin  Accord  50/850 mg,  50/1000 mg  film-coated  tablets  is  indicated  for  adult 
patients with type 2 diabetes mellitus. 
-  As  an  adjunct  to  diet  and  exercise  to  improve  glycaemic  control  in  patients  inadequately 
controlled on their maximal tolerated dose of metformin alone or those already being treated 
with the combination of sitagliptin and metformin. 
- 
In combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and 
exercise in patients inadequately controlled on their maximal tolerated dose of metformin and 
a sulphonylurea. 
-  As  triple  combination  therapy  with  a  peroxisome  proliferator-activated  receptor  gamma 
(PPARγ)  agonist  (i.e.,  a  thiazolidinedione)  as  an  adjunct  to  diet  and  exercise  in  patients 
inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist. 
-  As  add-on  to  insulin  (i.e.,  triple  combination  therapy)  as  an  adjunct  to  diet  and  exercise  to 
improve glycaemic control in patients when stable dose of insulin and metformin alone do not 
provide adequate glycaemic control. 
It contains sitagliptin and metformin as the active substances and it is given by oral route. 
Further information about the evaluation of Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg 
film-coated tablets’ benefits can be found in Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg 
film-coated tablets’ EPAR, including its plain language summary available on the EMA website, 
under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/sitagliptin-
metformin-hydrochloride-accord  
II. 
Risks associated with the medicine and activities to minimise or further characterise 
the risks 
Important  risks  of  Sitagliptin/Metformin  Accord  50/850 mg,  50/1000 mg  film-coated  tablets, 
together with measures to minimise such risks and the proposed studies for learning more about 
Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets, are outlined below. 
Measures to minimise the risks identified for medicinal products can be: 
•  Specific  information,  such  as  warnings,  precautions,  and  advice  on  correct  use,  in  the 
package leaflet and SmPC addressed to patients and healthcare professionals; 
• 
Important advice on the medicine’s packaging; 
•  The authorised pack size — the amount of medicine in a pack is chosen so to ensure that 
the medicine is used correctly; 
•  The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or 
without prescription) can help to minimise its risks. 
Together, these measures constitute routine risk minimisation measures. 
In addition to these measures, information about adverse reactions is collected continuously and 
regularly analysed, including PSUR assessment and signal management activity, so that immediate 
action can be taken as necessary. These measures constitute routine pharmacovigilance activities. 
If important information that may affect the safe use of Sitagliptin/Metformin Accord 50/850 mg, 
50/1000 mg film-coated tablets is not yet available, it is listed under ‘missing information’ below. 
II.A List of important risks and missing information 
Important risks of Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets are 
risks that need special risk management activities to further investigate or minimise the risk, so that 
the medicinal product can be safely taken. Important risks can be regarded as identified or potential. 
Identified  risks  are  concerns  for  which  there  is  sufficient  proof  of  a  link  with  the  use  of 
Sitagliptin/Metformin  Accord  50/850 mg,  50/1000 mg  film-coated  tablets.  Potential  risks  are 
concerns for which an association with the use of this medicine is possible based on available data, 
but this association has not been established yet and needs further evaluation. Missing information 
refers to information on the safety of the medicinal product that is currently missing and needs to 
be collected (e.g. on the long-term use of the medicine); 
Important identified risks 
•  Lactic acidosis 
Important potential risks 
•  Pancreatic cancer 
Missing Information 
•  Exposure during pregnancy and lactation 
II.B Summary of important risks 
The safety information in the proposed product information is aligned to the reference medicinal 
product. 
II.C Post-authorisation development plan 
II.C.1 Studies which are conditions of the marketing authorisation 
There are no studies which are conditions of the marketing authorization or specific obligation of 
Sitagliptin/Metformin Accord 50/850 mg, 50/1000 mg film-coated tablets. 
II.C.2 Other studies in post-authorisation development plan 
There  are  no  studies  required  for  Sitagliptin/Metformin  Accord  50/850 mg,  50/1000 mg  film-
coated tablets. 
 
